Preview

Нефрология

Расширенный поиск

Болезнь минимальных изменений и стероид-чувствительный нефротический синдром у детей: одна или две болезни?

Полный текст:

Аннотация

Более трех десятилетий прошло после глобального исследования ISKDC (1981) нефротического синдрома у детей, позволившего сделать определенные рекомендации, такие как не проводить нефробиопсию у детей в дебюте заболевания и в случае положительного ответа на стероидную терапию признавать у больного наличие болезни минимальных изменений. Однако в последние годы отмечается прирост ФСГС у детей с первичным НС, в дебюте которого возможна стероидная чувствительность. В связи с чем следует пересмотреть восприятие первичного нефротического синдрома в детском возрасте как доброкачественное с благоприятным исходом. Более того, болезнь минимальных изменений, в патогенезе которой традиционно рассматривали только клеточно-опосредованный механизм, может развиваться и при других нарушениях, таких как дисрегуляция экспрессии CD80 на подоцитах или деструкция подоцита в связи с мутацией генов структурных белков последнего.

Об авторе

Эдита Константиновна Петросян
Российский Национальный исследовательский медицинский университет
Россия


Список литературы

1. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndromefrom initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981;98(4):561-564

2. Boyer O., Moulder J.K., Somers Michael J.G. Focal and segmental glomerulosclerosis in children: a longitudinal assessment. Pediatric Nephrology 2007; 22 (8) http://link.springer.com/ journal/467/22/8/page/1: 1159-1166

3. Srivastava T., Simon S.D., Alon U.S. High incidence of focal segmental glomerulosclerosis in neph rotic syndrome of childhood. Pediatric Nephrology 1999; 13: 13-18

4. Moura L.R.R., Franco M.F., Kirsztajn G.M. Minimal change disease and focal segmental glomerulosclerosis in adults: response to steroids and risk of renal failure. J Bras Nefrol 2015;37(4):475-480

5. Siegel N.J., Gaudio K.M., Krassner L.S. et al. Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment. Kidney Int 1981:19(3):454-459

6. Webb N.J., Lewis M.A., Iqbal J. et al. Childhood steroidsensitive nephrotic syndrome: does the histology matter? Am J Kidney Dis 1996; 27(4):484-488

7. White R.H.R., Glasgow E.F., Mills R.J. Clinicopathological study of nephrotic syndrome in childhood. Lancet 1970; 1: 1353-1359

8. Gulati S., Sharma A.P., Sharma R.K. et al. Do current recommendations for kidney biopsy in nephrotic syndrome need modifications? Pediatric Nephrology 2002; 17: 404-408

9. Siegel N.J., Kashgarian M., Spargo B.H. Minimal change and focal sclerotic lesions in lipoid nephrosis. Nephron 1974; 13: 125-136

10. Kashgarian M., Hayslett J.P., Siegel N.J. Lipoid nephrosis and focal sclerosis distinct entities or spectrum of disease. Nephron 1974;13:105-108

11. Meyrier A. Epluribus unum: The riddle of focal-segmental glomerulosclerosis. Semin Nephrol 2003;23:135-140

12. Stokes B.M., Markowitz G.S., Lin J. et al. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Kidney Int 2004; 65:1690-1702

13. Shalhoub R.J. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974; 2:556-560

14. Lagrue G., Branellec A., Blanc C. et al. A vascular permeabilityfactor in lymphocyte culture supernatants from patients withnephrotic syndrome. II. Pharmacological and physicochemicalproperties. Biomedicine 1975; 23: 73-75

15. Tanaka R., Yoshikawa N., Nakamura H., Ito H. Infusion of peripheral blood mononuclear cell products from nephrotic children increases albuminuria in rats. Nephron 1992; 60: 35-41

16. Boulton Jones J.M., Tulloch I., Dore B. et al. Changes in the glomerular capillary wall induced by lymphocyte products and serum of nephrotic patients. Clin Nephrol 1983; 20: 72-77

17. Yoshizawa N., Kusumi Y., Matsumoto K. et al. Studies of a glomerular permeability factor in patients with minimal-chang enephrotic syndrome. Nephron 1989; 51: 370-376

18. Mayurama K., Tomizawa S., Shimabukuro N. et al. Effect of supernatants derived from T lymphocyte culture in minimal change nephrotic syndrome on rat kidney capillaries. Nephron 1989;51:73-76

19. Fodor P., Saitua M.T., Rodriguez E. et al. T-cell dysfunction inminimal-change nephrotic syndrome of childhood. Am J Dis Child 1982; 136: 713-717

20. Frank C., Herrmann M., Fernandez S. et al. Dominant T cells inidiopathic nephrotic syndrome of childhood. Kidney Int 2000; 57: 510-517

21. Cunard R., Kelly C.J. T cells and minimal change disease. J Am Soc Nephrol 2002; 13: 1409-1411

22. Shevach E.M., McHugh R.S., Piccirillo C.A., Thornton AM.Control of T-cell activation by CD4q CD25q suppressor T cells. Immunol Rev 2001; 182: 58-67

23. Hulton S.A., Neuhaus T.J., Callard R.E. et al. Circulating interleukin-2 receptor(IL2R) in ntphrotic syndrome. Kidney Int1997; 51(58): S83-S84

24. Glimcher L.H., Murphy K.M. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev 2000; 14: 1693-1711

25. Stefanovic V., Golubovic E., Mitic-Zlatkovic M. et al. Interleukin-12 and interferon-gamma production in childhood idio-pathicnephrotic syndrome. Pediatr Nephrol 1998; 12: 463-466

26. Ho I.C., Lo D., Glimcher L.H. c-maf promotes T helper cell type 2(Th2) and attenuates Th1 differentiation by both interleukin4-dependent and -independent mechanisms. J Exp Med 1998; 188: 1859-1866

27. Saxena S., Mittal A., Andal A. Pattern of interleukins in minimal- change nephrotic syndrome of childhood. Nephron 1993; 65: 56-61

28. Kimata H., Fujimoto M., Furusho K. Involvement of interleukin(IL)-13., but not IL-4., in spontaneous IgE and IgG4 productionin nephrotic syndrome. Eur J Immunol 1995; 25: 1497-1501

29. Fuke Y., Endo M., Ohsawa I et al. Implication of elevated serum IgE levels in minimal change nephrotic syndrome. Nephron 2002; 91: 769-770

30. Jos E.G., Berg V.D., Aten J et al. Interleukin-4 and Interleukin-13 Act on Glomerular Visceral Epithelial Cells. J Am Soc Nephrol 2000;11: 413-422

31. Van den Berg J.G., Aten J., Chand M.A. et al. Interleukin-4 and interleukin-13 act on glomerular visceral epithelial cells. J Am Soc Nephrol. 2000; 11: 413-422

32. Garin E.H. Circulating mediators of proteinuria in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol 2000; 14: 8-9: 872-878

33. Sahali D., Pawlak A., Valanciute A. et al. A novel approach toinvestigation of the pathogenesis of active minimal-changene-phrotic syndrome using subtracted cDNA library screening. J Am Soc Nephrol 2002; 13: 1238-1247

34. Das J., Chen C.H., Yang L. et al. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat Immunol 2001; 2: 45-50

35. Sahali D., Pawlak A., Le Gouvello S. et al. Transcriptional and post-transcriptional alterations of I kappa B alpha in active minimal-change nephrotic syndrome. J Am Soc Nephrol 2001; 12: 1648-1658

36. Cao C., Lu S., Dong C. et al. Abnormal DNA-binding of transcription factors in minimal change nephrotic syndrome. Pediatr Nephrol 2001; 16: 790-795

37. Reiser J., von Gersdorff G., Loos M. et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004;113:1390-1397

38. Wing K., Onishi Y., Prieto-Martin P. et al. CTLA-4 control over Foxp3 regulatory T cell function. Science 2008; 322: 271-275

39. Reiser J., Mundel P. Danger signaling by glomerular podocytes defines a novel function of inducible B7-1 in the pathogenesis of nephrotic syndrome. J Am Soc Nephrol 2004;15:2246-2248

40. Yu C.C., Fornoni A., Weins A. et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013;369:2416-2423

41. Garin E.H., Mu W., Arthur J.M. et al. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 2010;78: 296-302

42. Lai K.W., Wei C.L., Tan L.K. et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol 2007;18:1476-1485

43. Ishimoto T., Cara-Fuentes G., Wang H. et al. Serum from minimal change patients in relapse increases CD80 expression in cultured podocytes. Pediatr Nephrol 2013 Sep;28(9):1803-1812

44. Ishimoto T., Shimada M., Gabriela G. et al. Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice. Nephrol Dial Transplant 2013; 28(6):1439-1446

45. Kerjaschki D. Caught flat-f ooted: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001;108:1583-1587

46. Drenckhahn D., Franke R.P. Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytes of chicken, rat, and man. Lab Invest 1988;59: 673-682

47. Mundel P., Gilbert P., Kriz W. Podocytes in glomerulus of rat kidney express a characteristic 44 KD protein. J Histochem Cytochem 1991; 39: 1047-1056

48. Adler S. Characterization of glomerular epithelial cell matrix receptors. Am J Pathol 1992;141: 571-578

49. Regele H.M., Fillipovic E., Langer B., et al: Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis. J Am Soc Nephrol 2000;11: 403-412

50. Kreidberg J.A., Symons J.M. Integrins in kidney development, function, and disease. Am J Physiol Renal Physiol 2000; 279: 233-242

51. Heinrich M. Regele, Edith Fillipovic, Brigitte Lancer et al. Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis. J Am Sjc Nephrol 2000;11:403-412

52. Durbeej M., Henry M.D., Campbell K.P. Dystroglycan in development and disease. Curr Opin Cell Biol 1998; 10: 594-601

53. Hemler M.E. Dystroglycan versatility. Cell 1999; 97:543-546

54. Raats C.J., van den Born J., Bakker M.A. et al. Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies. Am J Pathol 2000; 156: 1749-1765

55. Regele H.M., Fillipovic E., Langer B. et al. Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis. J Am Soc Nephrol 2000; 11: 403-412

56. Williamson R.A., Henry M.D., Daniels K.J. et al. Dystroglycan is essential for ealy embryonic development: Disruption of Reichert’s membrane in Dag1-null mise. Hum Mol Gen 1997;6: 831-841

57. Tryggvason K., Wartiovaara J. Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 2001;10: 543-549

58. Kestila M., Lenkkeri U., Mannikko M. et al. Positionally cloned gene for a novel glomerular protein - nephrin - is mutated in congenital nephrotic syndrome. Mol Cel 1998;1: 575-582

59. Boute N., Gribouval O., Roselli S. et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000;24: 349-354

60. Kaplan J.M., Kim S.H., North K.N. et al. Mutations in ACTN4, encoding alpha-a ctinin-4 , cause familial focal segmental glomerulosclerosis. Nat Genet 2000; 24: 251-256

61. Reiser J., Polu K.R., Moller C.C. et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 2005;37: 739-744

62. Machuca E., Benoit G., Antignac C. Genetics of nephrotic syndrome: connecting molecular genetics to podocyte physiology. Hum Mol Genet 2009; 18(R2): 185-194

63. Carrasco-Miranda J.S., Garcia-Alvarez R., Sotelo-Mundo R.R. et al. Mutations in NPHS2 (podocin) in Mexican children with nephrotic syndrome who respond to standard steroid treatment. Genet Mol Res 2013; 24;12(2):2102-2107

64. Lahdenkari Н.А., Кестиля М., Holmberg С. et al. Nephrin ген (NPHS1) у пациентов с минимальным изменением нефротическим синдромом (MCNS). Kidney Int 2004; 65 (5): 1856-1863

65. Mottl A.K., Lu M., Fine C.A., Weck K.E. A novel TRPC6 mutation in a family with podocytopathy and clinical variability. BMC Nephrol 2013 May 10;14:104

66. Петросян Э.К., Цыгин А.Н., Ильенко Л.И. и др. Полиморфный маркер R229Q гена подоцина у детей с нефротическим синдромом. Нефрологияидиализ 2006; 8(3): 268-271

67. Gee H.Y., Ashraf S., Wan X. et al. Mutations in EMP2 cause childhood-onset nephrotic syndrome. Am J Hum Genet 2014: 5;94(6):884-890


Для цитирования:


Петросян Э.К. Болезнь минимальных изменений и стероид-чувствительный нефротический синдром у детей: одна или две болезни? Нефрология. 2016;20(2):33-38.

For citation:


Petrosyan E.K. Minimal change disease and steroids sensitive nephrotic syndrome in children: one or two diseases? Nephrology (Saint-Petersburg). 2016;20(2):33-38. (In Russ.)

Просмотров: 541


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)